tetano
Editor, Senior Moderator
J Infect Dis. 2019 Jul 9. pii: jiz360. doi: 10.1093/infdis/jiz360. [Epub ahead of print]
[h=1]Effect of age on relative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries ages 65 years and older.[/h] Lu Y[SUP]1[/SUP], Chillarige Y[SUP]2[/SUP], Izurieta HS[SUP]1,[/SUP][SUP]3[/SUP], Wei Y[SUP]2[/SUP], Xu W[SUP]2[/SUP], Lu M[SUP]2[/SUP], Sung HM[SUP]2[/SUP], Lindaas A[SUP]2[/SUP], Wernecke M[SUP]2[/SUP], MaCurdy T[SUP]2,[/SUP][SUP]4[/SUP], Kelman J[SUP]5[/SUP], Forshee RA[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Studies have found that the high-dose influenza vaccine has higher relative vaccine effectiveness (RVE) compared to standard-dose vaccines in some seasons. We evaluated the effect of age on the high-dose versus standard-dose RVE among Medicare beneficiaries.
[h=4]METHODS:[/h] A six-season retrospective cohort study from 2012 to 2018 among Medicare beneficiaries ages ≥65 years. Poisson regression was used to evaluate the effect of age on high-dose versus standard-dose RVE in preventing influenza hospitalizations.
[h=4]RESULTS:[/h] The study included >19 million vaccinated beneficiaries in a community pharmacy setting. The Poisson models indicated a slightly increasing trend in RVE with age in all seasons. The high-dose vaccine was more effective than standard-dose vaccines in preventing influenza hospital encounters (influenza inpatient stays and emergency department visits) in the 2012-13 (RVE 23.1%, 95% CI 17.6-28.3%), 201314 (RVE 15.3%, 95% CI 7.8-22.3%), 201415 (RVE 8.9%, 95% CI 5.6-12.1%), and 201617 (RVE 12.6%, 95% CI 6.3-18.4%) seasons, and was at least as effective in all other seasons. We also found that the high-dose vaccine was consistently more effective than standard-dose vaccines for people ages ≥85 years across all seasons. Similar trends were observed for influenza inpatient stays.
[h=4]CONCLUSIONS:[/h] The high-dose versus standard-dose influenza vaccine RVE increases with age.
Published by Oxford University Press for the Infectious Diseases Society of America 2019. This work is written by (a) US Government employee(s) and is in the public domain in the US.
[h=4]KEYWORDS:[/h] Medicare; effect of age; high-dose vaccine; influenza vaccine; relative vaccine effectiveness
PMID: 31290553 DOI: 10.1093/infdis/jiz360
[h=1]Effect of age on relative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries ages 65 years and older.[/h] Lu Y[SUP]1[/SUP], Chillarige Y[SUP]2[/SUP], Izurieta HS[SUP]1,[/SUP][SUP]3[/SUP], Wei Y[SUP]2[/SUP], Xu W[SUP]2[/SUP], Lu M[SUP]2[/SUP], Sung HM[SUP]2[/SUP], Lindaas A[SUP]2[/SUP], Wernecke M[SUP]2[/SUP], MaCurdy T[SUP]2,[/SUP][SUP]4[/SUP], Kelman J[SUP]5[/SUP], Forshee RA[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Studies have found that the high-dose influenza vaccine has higher relative vaccine effectiveness (RVE) compared to standard-dose vaccines in some seasons. We evaluated the effect of age on the high-dose versus standard-dose RVE among Medicare beneficiaries.
[h=4]METHODS:[/h] A six-season retrospective cohort study from 2012 to 2018 among Medicare beneficiaries ages ≥65 years. Poisson regression was used to evaluate the effect of age on high-dose versus standard-dose RVE in preventing influenza hospitalizations.
[h=4]RESULTS:[/h] The study included >19 million vaccinated beneficiaries in a community pharmacy setting. The Poisson models indicated a slightly increasing trend in RVE with age in all seasons. The high-dose vaccine was more effective than standard-dose vaccines in preventing influenza hospital encounters (influenza inpatient stays and emergency department visits) in the 2012-13 (RVE 23.1%, 95% CI 17.6-28.3%), 201314 (RVE 15.3%, 95% CI 7.8-22.3%), 201415 (RVE 8.9%, 95% CI 5.6-12.1%), and 201617 (RVE 12.6%, 95% CI 6.3-18.4%) seasons, and was at least as effective in all other seasons. We also found that the high-dose vaccine was consistently more effective than standard-dose vaccines for people ages ≥85 years across all seasons. Similar trends were observed for influenza inpatient stays.
[h=4]CONCLUSIONS:[/h] The high-dose versus standard-dose influenza vaccine RVE increases with age.
Published by Oxford University Press for the Infectious Diseases Society of America 2019. This work is written by (a) US Government employee(s) and is in the public domain in the US.
[h=4]KEYWORDS:[/h] Medicare; effect of age; high-dose vaccine; influenza vaccine; relative vaccine effectiveness
PMID: 31290553 DOI: 10.1093/infdis/jiz360